18 results on '"Hobson, Claire Amaris"'
Search Results
2. Evaluation of the Specificity of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Classification for Infective Endocarditis.
- Author
-
Moisset, Hugo, Rio, Julien, Benhard, Johan, Arnoult, Florence, Deconinck, Laurene, Grall, Nathalie, Iung, Bernard, Lescure, Xavier, Rouzet, François, Suc, Gaspard, Hoen, Bruno, Hobson, Claire Amaris, and Duval, Xavier
- Subjects
COMMUNICABLE diseases ,BLOOD ,CARDIOVASCULAR diseases ,ACADEMIC medical centers ,SCIENTIFIC observation ,INFECTIVE endocarditis ,INTERNATIONAL agencies ,RETROSPECTIVE studies ,CELL culture ,ELECTRONIC health records ,CONFIDENCE intervals ,SENSITIVITY & specificity (Statistics) ,ECHOCARDIOGRAPHY ,PATIENT aftercare - Abstract
Background The 2023 Duke-ISCVID (International Society of Cardiovascular Infectious Diseases) classification is a new diagnostic tool for infective endocarditis, updating the 2000 modified Duke and the 2015 European Society for Cardiology (ESC) classifications. In comparison, its sensitivity is higher; however, its specificity remains to be evaluated and compared to that of the 2 other classifications in endocarditis suspected patients. Methods We retrospectively collected the characteristics of patients hospitalized in Bichat University's Hospital, Paris, in 2021, who had been evaluated for clinical suspicion of endocarditis, have had at least a transthoracic echocardiography, 2 pairs of blood cultures, 3-month follow-up and in whom endocarditis diagnosis was finally rejected. All patients were classified by 2000 modified Duke, 2015 ESC and 2023 Duke-ISCVID, as though the endocarditis diagnosis had not been rejected. Results In total, 130 patients' charts were analyzed. Mean age was 62 years, 84 (64.6%) were male, 39 (30.0%) had prosthetic cardiac valve or valve repair, 21 (16.2%) cardiac implanted electronic device, and 30 (23.1%) other cardiac conditions. Overall, 5, 2, and 5 patients were falsely classified as definite endocarditis with the 2000 modified Duke, 2015 ESC, and 2023 Duke-ISCVID classifications, respectively. The corresponding specificities were 96.2% (95% confidence interval [CI] [90.8%, 98.6%]), 98.5% (95% CI [93.9%, 99.7%]), and 96.2% (95% CI [90.8%, 98.6%]). The rates of possible endocarditis were of 38%, 35%, and 35% in the 3 classifications, respectively. Conclusions The 2023 Duke-ISCVID classification is highly specific for ruling out the diagnosis of definite infective endocarditis in patients who had been evaluated for IE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Enterococcal endocarditis management and relapses.
- Author
-
Garofoli, Nina, Joly, Véronique, Pluart, Diane Le, Hobson, Claire Amaris, Beaumont, Anne-Lise, Lariven, Sylvie, Grall, Nathalie, Para, Marylou, Yazdanpanah, Yazdan, Lescure, François-Xavier, Peiffer-Smadja, Nathan, Deconinck, Laurène, and Thy, Michael
- Published
- 2024
- Full Text
- View/download PDF
4. Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam
- Author
-
Hobson, Claire Amaris, Bonacorsi, Stéphane, Hocquet, Didier, Baruchel, André, Fahd, Mony, Storme, Thomas, Tang, Raksamy, Doit, Catherine, Tenaillon, Olivier, and Birgy, André
- Published
- 2020
- Full Text
- View/download PDF
5. A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin.
- Author
-
Hobson, Claire Amaris, Vigué, Lucile, Magnan, Mélanie, Chassaing, Benoit, Naimi, Sabrine, Gachet, Benoit, Claraz, Pauline, Storme, Thomas, Bonacorsi, Stephane, Tenaillon, Olivier, and Birgy, André
- Subjects
HUMAN microbiota ,GUT microbiome ,DAUNOMYCIN ,DRUG efficacy ,ANTINEOPLASTIC agents - Abstract
Background: Anticancer drug efficacy is linked to the gut microbiota's composition, and there is a dire need to better understand these interactions for personalized medicine. In vitro microbiota models are promising tools for studies requiring controlled and repeatable conditions. We evaluated the impact of two anticancer drugs on human feces in the MiniBioReactor Array (MBRA) in vitro microbiota system. Methods: The MBRA is a single-stage continuous-flow culture model, hosted in an anaerobic chamber. We evaluated the effect of a 5-day treatment with hydroxycarbamide or daunorubicine on the fecal bacterial communities of two healthy donors. 16S microbiome profiling allowed analysis of microbial richness, diversity, and taxonomic changes. Results: In this host-free setting, anticancer drugs diversely affect gut microbiota composition. Daunorubicin was associated with significant changes in alpha- and beta-diversity as well as in the ratio of Firmicutes/Bacteroidetes in a donor-dependent manner. The impact of hydroxycarbamide on microbiota composition was not significant. Conclusion: We demonstrated, for the first time, the impact of anticancer drugs on human microbiota composition, in a donor- and molecule-dependent manner in an in vitro human microbiota model. We confirm the importance of personalized studies to better predict drug-associated-dysbiosis in vivo , linked to the host's response to treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Clinical impact of a gastrointestinal PCR panel in children with infectious diarrhoea.
- Author
-
Truong, Jeanne, Cointe, Aurélie, Le Roux, Enora, Bidet, Philippe, Michel, Morgane, Boize, Julien, Mariani-Kurkdjian, Patricia, Caseris, Marion, Hobson, Claire Amaris, Desmarest, Marie, Titomanlio, Luigi, Faye, Albert, and Bonacorsi, Stéphane
- Subjects
SHIGELLOSIS ,DIARRHEA ,MEDICAL care ,MILK allergy ,ANTIBIOTICS ,GASTROENTERITIS ,ESCHERICHIA coli ,FECES ,IMPACT of Event Scale ,POLYMERASE chain reaction - Abstract
Objectives: Multiplex gastrointestinal PCR (GI-PCR) allows fast and simultaneous detection of 22 enteric pathogens (including Campylobacter, Salmonella, Shigella/enteroinvasive Escherichia coli (EIEC), among other bacteria, parasites and viruses). However, its impact on the management of children with infectious diarrhoea remains unknown.Patients/design: All children eligible for stool culture from May to October 2018 were prospectively included in a monocentric study at Robert-Debré University-Hospital.Intervention: A GI-PCR (BioFire FilmArray) was performed on each stool sample.Main Measures: Data on the children's healthcare management before and after GI-PCR results were collected. Stool culture results were also reported.Results: 172 children were included. The main criteria for performing stool analysis were mucous/bloody diarrhoea and/or traveller's diarrhoea (n=130). GI-PCR's were positive for 120 patients (70%). The main pathogens were enteroaggregative E. coli (n=39; 23%), enteropathogenic E. coli (n=34; 20%), Shigella/EIEC (n=27; 16%) and Campylobacter (n=21; 12%). Compared with stool cultures, GI-PCR enabled the detection of 21 vs 19 Campylobacter, 12 vs 10 Salmonella, 27 Shigella/EIEC vs 13 Shigella, 2 vs 2 Yersinia enterocolitica, 1 vs 1 Plesiomonas shigelloides, respectively. Considering the GI-PCR results and before stool culture results, the medical management was revised for 40 patients (23%): 28 initiations, 2 changes and 1 discontinuation of antibiotics, 1 hospitalisation, 2 specific room isolations related to Clostridioides difficile infections, 4 additional test prescriptions and 2 test cancellations.Conclusion: The GI-PCR's results impacted the medical management of gastroenteritis for almostone-fourth of the children, and especially the prescription of appropriate antibiotic treatment before stool culture results. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Local and Global Protein Interactions Contribute to Residue Entrenchment in Beta-Lactamase TEM-1.
- Author
-
Birgy, André, Magnan, Mélanie, Hobson, Claire Amaris, Figliuzzi, Matteo, Panigoni, Karine, Codde, Cyrielle, Tenaillon, Olivier, and Jacquier, Hervé
- Subjects
BETA lactamases ,PROTEIN-protein interactions ,BETA lactam antibiotics ,PROTEIN stability ,PROTEIN models ,AMINO acids - Abstract
Due to their rapid evolution and their impact on healthcare, beta-lactamases, protein degrading beta-lactam antibiotics, are used as generic models of protein evolution. Therefore, we investigated the mutation effects in two distant beta-lactamases, TEM-1 and CTX-M-15. Interestingly, we found a site with a complex pattern of genetic interactions. Mutation G251W in TEM-1 inactivates the protein's function, just as the reciprocal mutation, W251G, does in CTX-M-15. The phylogenetic analysis revealed that mutation G has been entrenched in TEM-1's background: while rarely observed throughout the phylogeny, it is essential in TEM-1. Using a rescue experiment, in the TEM-1 G251W mutant, we identified sites that alleviate the deviation from G to W. While few of these mutations could potentially involve local interactions, most of them were found on distant residues in the 3D structure. Many well-known mutations that have an impact on protein stability, such as M182T, were recovered. Our results therefore suggest that entrenchment of an amino acid may rely on diffuse interactions among multiple sites, with a major impact on protein stability. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Intrauterine infection caused by nontyphoidal : a literature review.
- Author
-
Mollo, Bastien, Hobson, Claire Amaris, Le Hello, Simon, Azria, Elie, Le Monnier, Alban, Pilmis, Benoit, and Mizrahi, Assaf
- Abstract
Objectives: Although nontyphoidal Salmonella infections have a prevalence of 0.2-1.8%. It is mostly described in veterinary medicine; it could be responsible for severe intra-amniotic infections in humans. The objective of this review is to describe the clinical and microbiological aspects of intrauterine infection (IUI) caused by nontyphoidal Salmonella.Methods: We reported a case analysis and subsequently conducted a systematic literature review of IUI caused by nontyphoidal Salmonella between 1966 and 2018.Results: In literature nine cases have been reported, and were confirmed by the identification of a nontyphoidal Salmonella in the biological samples. Our review reveals severe clinical presentations in pregnant women. Indeed, sepsis, spontaneous abortions, and fatal outcomes for fetuses were described in 90, 60, and 80% of the cases, respectively. The major clinical symptoms were in majority acute, with high fever, abdominal pain, metrorrhagia, and premature membranes ruptures. Nulliparity is a risk factor and the prognosis depends on the pregnancy stage. All mothers received antibiotics and their outcomes were favorable.Conclusions: Nontyphoidal Salmonella infections can be responsible for severe pregnancy complications. Considering the severe neonatal prognosis, in case of a history of diarrhea and/or sepsis, a search for this pathogen should be considered, and a preventive strategy could be discussed during pregnancy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
- Author
-
Birgy, André, Madhi, Fouad, Jung, Camille, Levy, Corinne, Cointe, Aurélie, Bidet, Philippe, Hobson, Claire Amaris, Bechet, Stéphane, Sobral, Elsa, Vuthien, Hoang, Ferroni, Agnès, Aberrane, Saïd, Cuzon, Gaëlle, Beraud, Laetitia, Gajdos, Vincent, Launay, Elise, Pinquier, Didier, Haas, Hervé, Desmarest, Marie, and Dommergues, Marie-Aliette
- Subjects
CHILD patients ,CLAVULANIC acid ,ORAL drug administration ,TREATMENT effectiveness ,URINARY tract infections ,AMOXICILLIN ,CEFTAZIDIME ,RESEARCH ,RESEARCH methodology ,CEFOTAXIME ,MEDICAL cooperation ,EVALUATION research ,PENICILLIN ,COMPARATIVE studies ,ANTIBIOTICS ,PHARMACODYNAMICS - Abstract
Objectives: Oral treatment of febrile urinary tract infections (FUTIs) can be impaired by MDR Enterobacterales often combining ESBL and inhibitor-resistant genes. We studied the impact of β-lactamases and Enterobacterales' genotypes on the cefixime, cefpodoxime and mecillinam ± amoxicillin/clavulanate MICs.Materials and Methods: In this multicentric study, we included 251 previously whole-genome-sequenced ESBL-producing Enterobacterales, isolated in French children with FUTIs. The MICs of cefixime, cefpodoxime, mecillinam alone and combined with amoxicillin/clavulanate were determined and analysed with respect to genomic data. We focused especially on the isolates' ST and their type of β-lactamases. Clinical outcomes of patients who received cefixime + amoxicillin/clavulanate were also analysed.Results: All isolates were cefixime and cefpodoxime resistant. Disparities depending on blaCTX-M variants were observed for cefixime. The addition of amoxicillin/clavulanate restored susceptibility for cefixime and cefpodoxime in 97.2% (MIC50/90 of 0.38/0.75 mg/L) and 55.4% (MIC50/90 of 1/2 mg/L) of isolates, respectively, whatever the ST, the blaCTX-M variants or the association with inhibitor-resistant β-lactamases (34.2%). All isolates were susceptible to mecillinam + amoxicillin/clavulanate with MIC50/90 of 0.19/0.25 mg/L, respectively. Neither therapeutic failure nor any subsequent positive control urine culture were reported for patients who received cefixime + amoxicillin/clavulanate as an oral relay therapy (n = 54).Conclusions: Despite the frequent association of ESBL genes with inhibitor-resistant β-lactamases, the cefixime + amoxicillin/clavulanate MICs remain low. The in vivo efficacy of this combination was satisfying even when first-line treatment was ineffective. Considering the MIC distributions and pharmacokinetic parameters, mecillinam + amoxicillin/clavulanate should also be an alternative to consider when treating FUTIs in children. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales
- Author
-
Danjean, Maxime, Hobson, Claire Amaris, Gits-Muselli, Maud, Courroux, Céline, Monjault, Audrey, Bonacorsi, Stéphane, and Birgy, André
- Published
- 2022
- Full Text
- View/download PDF
11. Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- Author
-
Hobson, Claire Amaris, Cointe, Aurélie, Jacquier, Hervé, Choudhury, Alaksh, Magnan, Mélanie, Courroux, Céline, Tenaillon, Olivier, Bonacorsi, Stéphane, and Birgy, André
- Published
- 2021
- Full Text
- View/download PDF
12. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017.
- Author
-
Birgy, André, Madhi, Fouad, Jung, Camille, Levy, Corinne, Cointe, Aurélie, Bidet, Philippe, Hobson, Claire Amaris, Bechet, Stéphane, Sobral, Elsa, Vuthien, Hoang, Ferroni, Agnès, Aberrane, Saïd, Cuzon, Gaëlle, Beraud, Laetitia, Gajdos, Vincent, Launay, Elise, Pinquier, Didier, Haas, Hervé, Desmarest, Marie, and Dommergues, Marie-Aliette
- Subjects
URINARY tract infections ,ENTEROBACTERIACEAE ,COMMUNICABLE diseases ,KLEBSIELLA pneumoniae ,BETA lactamases ,ESCHERICHIA coli ,RESEARCH ,FEVER ,GENETICS ,RESEARCH methodology ,ENTEROBACTERIACEAE diseases ,MEDICAL cooperation ,EVALUATION research ,SEROTYPES ,COMPARATIVE studies ,DRUG resistance in microorganisms ,ANTIBIOTICS ,LONGITUDINAL method ,MICROBIAL sensitivity tests ,TOXINS ,PHARMACODYNAMICS - Abstract
Background: The population structure of extraintestinal pathogenic Escherichia coli evolves over time, notably due to the emergence of antibiotic-resistant clones such as ESBL-producing Enterobacteriaceae (ESBL-E).Objectives: To analyse by WGS the genetic diversity of a large number of ESBL-E isolated from urinary tract infections in children from paediatric centres across France between 2014 and 2017 and collected by the National Observatory of febrile urinary tract infection (FUTI) caused by ESBL-E.Methods: A total of 40 905 Enterobacteriaceae-positive urine cultures were identified. ESBL-E were found in 1983 samples (4.85%). WGS was performed on 251 ESBL-E causing FUTI. STs, core genome MLST (cgMLST), serotype, fimH allele, ESBL genes and presence of papGII key virulence factor were determined.Results: E. coli and Klebsiella pneumoniae were found in 86.9% (218/251) and 11.2% (28/251) of cases, respectively. Several STs predominate among E. coli such as ST131, ST38, ST69, ST73, ST95, ST405, ST12 and ST1193, while no ST emerged in K. pneumoniae. E. coli ST131, ST38 and ST1193 increased during the study period, with a heterogeneity in papGII prevalence (64.5%, 35% and 20% respectively). Most isolates harboured the CTX-M type (97%) with a predominance of blaCTX-M-15. blaCTX-M-27, an emerging variant in E. coli, is found in various STs. cgMLST enabled discrimination of clusters within the main STs.Conclusions: The predominance of ST131, and the emergence of other STs such as ST38 and ST1193 combined with ESBL genes deserves close epidemiological surveillance considering their high threat in infectious disease. cgMLST could be a discriminant complementary tool for the analyses. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Rapid Carbapenemase Detection With Xpert Carba-R V2 Directly On Positive Blood Vials.
- Author
-
Cointe, Aurélie, Walewski, Violaine, Hobson, Claire Amaris, Doit, Catherine, Bidet, Philippe, Dortet, Laurent, Bonacorsi, Stéphane, and Birgy, André
- Subjects
CARBAPENEMASE ,INFECTION prevention ,VIALS ,BLOOD ,TIME management - Abstract
The rapid detection of carbapenemase allows implementation of infection control measures and adaptation of antibiotic therapy. We evaluated the performances of the Xpert Carba-R V2
® assay for the direct detection and identification of carbapenemase on positive blood cultures. We focused our evaluation on its detection capacity and on the risks of interference due to the patient's blood. Isolates of several variants of OXA-48-like (n=10), KPC (n=10), NDM (n=11), VIM (n=7), IMP-1 (n=1) carbapenemases and 14 non carbapenemase-producing Enterobacteriaceae were tested. For each isolate (n=53), an aerobic vial was seeded, and incubated in Bactec Fx (Becton Dickinson® ) automate. When positive, the Xpert® Carba-R-V2 assay was assessed for carbapenemase detection using 40 μl aliquot. Reproducibility tests were performed on a subset of 23 isolates using aerobic and anaerobic vials. Longer incubation time was also evaluated on 6 isolates. A complementary prospective study in real-time testing of patient-derived clinical samples on 20 additional positive blood vials with Gram negative bacilli on direct examination was performed. Perfect sensitivity and specificity (100%) were observed regardless of the carbapenemase type, the blood vials used and the time of incubation. Xpert® Carba-R-V2 assay is suitable for the rapid detection of the main carbapenemase genes directly on positive blood vials. Its performances and rapid time analysis allow its use in routine to guide therapeutic choices and to implement infection control measures. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. Urine zinc concentrations allow proper expression of metallo-β-lactamases in Enterobacteriaceae.
- Author
-
Hobson, Claire Amaris, Cointe, Aurélie, Bidet, Philippe, Poupon, Joel, Bonacorsi, Stéphane, and Birgy, André
- Subjects
- *
ENTEROBACTERIACEAE , *ZINC , *URINE , *BETA lactam antibiotics , *BETA lactamases , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *HYDROLASES , *COMPARATIVE studies , *MEDICAL artifacts , *DRUG resistance in microorganisms , *ANTIBIOTICS , *PHARMACODYNAMICS - Abstract
Urine zinc concentrations allow proper expression of metallo- -lactamases in Enterobacteriaceae. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
15. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
- Author
-
Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, Jacquier H, and Birgy A
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Bacterial Proteins genetics, Carbapenems pharmacology, Drug Combinations, Humans, Klebsiella Infections drug therapy, Klebsiella Infections microbiology, Microbial Sensitivity Tests, beta-Lactamase Inhibitors pharmacology, beta-Lactamases genetics, Azabicyclo Compounds pharmacology, Azabicyclo Compounds therapeutic use, Ceftazidime pharmacology, Ceftazidime therapeutic use, Drug Resistance, Multiple, Bacterial, Klebsiella pneumoniae drug effects
- Abstract
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam. After the marketing of ceftazidime-avibactam, numerous variants of KPC resistant to this association have been described among isolates recovered from clinical samples or derived from experimental studies. In KPC variants resistant to ceftazidime-avibactam, point mutations, insertions and/or deletions have been described in various hot spots. Deciphering the impact of these mutations is crucial, not only from a therapeutic point of view, but also to follow the evolution in time and space of KPC variants resistant to ceftazidime-avibactam. In this review, we describe the mutational landscape of the KPC beta-lactamase toward ceftazidime-avibactam resistance based on a multidisciplinary approach including epidemiology, microbiology, enzymology, and thermodynamics. We show that resistance is associated with three hot spots, with a high representation of insertions and deletions compared with other class A beta-lactamases. Moreover, extension of resistance to ceftazidime-avibactam is associated with a trade-off in the resistance to other beta-lactams and a decrease in enzyme stability. Nevertheless, the high natural stability of KPC could underlay the propensity of this enzyme to acquire in vivo mutations conferring resistance to ceftazidime-avibactam (CAZavi), particularly via insertions and deletions.
- Published
- 2022
- Full Text
- View/download PDF
16. Azithromycin Resistance in Shiga Toxin-Producing Escherichia coli in France between 2004 and 2020 and Detection of mef (C)- mph (G) Genes.
- Author
-
Bizot E, Cointe A, Bidet P, Mariani-Kurkdjian P, Hobson CA, Courroux C, Liguori S, Bridier-Nahmias A, Magnan M, Merimèche M, Caméléna F, Berçot B, Weill FX, Lefèvre S, Bonacorsi S, and Birgy A
- Subjects
- Azithromycin pharmacology, Humans, Plasmids genetics, Escherichia coli Infections drug therapy, Escherichia coli Proteins genetics, Shiga-Toxigenic Escherichia coli genetics
- Abstract
We described and characterized Shiga-toxin-producing Escherichia coli (STEC) strains with high levels of resistance to azithromycin isolated in France between 2004 and 2020. Nine of 1,715 (0.52%) STEC strains were resistant to azithromycin, with an increase since 2017. One isolate carried a plasmid-borne mef (C)- mph (G) gene combination, described here for the first time for E. coli. Azithromycin resistance, although rare, needs consideration, as this treatment may be useful in cases of STEC infection.
- Published
- 2022
- Full Text
- View/download PDF
17. KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam.
- Author
-
Hobson CA, Bonacorsi S, Jacquier H, Choudhury A, Magnan M, Cointe A, Bercot B, Tenaillon O, and Birgy A
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Bacterial Proteins genetics, Drug Combinations, Humans, Klebsiella pneumoniae genetics, Microbial Sensitivity Tests, beta-Lactamases genetics, Azabicyclo Compounds pharmacology, Ceftazidime pharmacology, Klebsiella Infections drug therapy
- Abstract
To explore the mutational possibilities of insertions and deletions (indels) in the Klebsiella pneumoniae carbapenemase (KPC) beta-lactamase, we selected for ceftazidime-avibactam-resistant mutants. Of 96 screened mutants, we obtained 19 indels (2 to 15 amino acids), all located in the loops surrounding the active site. Three antibiotic susceptibility phenotypes emerged: an extended-spectrum-beta-lactamase-like phenotype, an activity restricted to ceftazidime, and a carbapenem-susceptible KPC-like phenotype. Tolerance for indels reflects the evolvability of KPC beta-lactamase, which could challenge the therapeutic management of patients., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
18. Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.
- Author
-
Hobson CA, Bonacorsi S, Fahd M, Baruchel A, Cointe A, Poey N, Jacquier H, Doit C, Monjault A, Tenaillon O, and Birgy A
- Subjects
- Anti-Bacterial Agents therapeutic use, Bacteremia microbiology, Cephalosporinase genetics, Child, Preschool, Drug Combinations, Enterobacteriaceae Infections microbiology, Female, Hematologic Neoplasms, Humans, Microbial Sensitivity Tests, Morganella morganii genetics, Morganella morganii isolation & purification, Azabicyclo Compounds therapeutic use, Aztreonam therapeutic use, Bacteremia drug therapy, Ceftazidime therapeutic use, Enterobacteriaceae Infections drug therapy, Morganella morganii drug effects, beta-Lactamases genetics
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.